nach oben

Archives of Virology

Erschienen in:

06.03.2020 | Original Article

Human respiratory syncytial virus F protein expressed in Pichia pastoris or Escherichia coli induces protective immunity without inducing enhanced respiratory disease in mice

verfasst von: Hai Li, Lei Cao, Yan Zhang, Hu Ren, Peibei Zhao, Wenbo Xu

Erschienen in: Archives of Virology | Ausgabe 5/2020

Einloggen, um Zugang zu erhalten

Abstract

Human respiratory syncytial virus (hRSV) is the primary cause of severe respiratory tract disease in children and infants as well as in elderly and immunocompromised adults. The fusion protein (F) of hRSV is the major antigen eliciting a neutralizing antibody response and protective immunity in the host, especially those recognizing the prefusion F protein (pre-F). In this study, we made genetic constructs for expression of a recombinant prefusion F protein in Pichia pastoris GS115, called RGF. Using Escherichia coli BL21, we expressed the pre-F and postfusion F protein (Post-F), called RBF and Post-RBF, respectively. RGF and RBF showed high affinity for 5C4, a highly potent monoclonal antibody specific for pre-F. We studied the immunogenicity of RGF and RBF in mice. Compared to mice immunized with formalin-inactivated RSV (FI-RSV), mice immunized with RGF or RBF exhibited superior protective immunity, which was confirmed by serum neutralizing activity and viral clearance after challenge. As judged from the IgG1/IgG2a ratios and numbers of IFN-γ- and IL-4-secreting cells, RGF or RBF with alum adjuvant induced a balanced Th1-biased immune response and produced no signs of enhanced respiratory disease (ERD) upon hRSV challenge. In addition, the immunogenicity and protective efficacy of RGF were superior to those of RBF in mice. Therefore, RGF represents a potential vaccine candidate for the prevention of human infection with hRSV.

Nur mit Berechtigung zugänglich

Amarasinghe GK, Ceballos NG, Banyard AC, Basler CF, Bavari S, Bennett AJ et al (2018) Taxonomy of the order Mononegavirales: update 2018. Arch Virol 163(8):2283–2294. https://doi.org/10.1007/s00705-018-3814-xCrossRef

Chanock R, Finberg L (1957) Recovery from infants with respiratory illness of a virus related to chimpanzee coryza agent (CCA). II. Epidemiologic aspects of infection in infants and young children. Am J Hyg 66(3):291–300

Karron RA, Black RE (2017) Determining the burden of respiratory syncytial virus disease: the known and the unknown. Lancet 390(10098):917–918. https://doi.org/10.1016/S0140-6736(17)31476-9CrossRef

Schickli JH, Whitacre DC, Tang RS, Kaur J, Lawlor H, Peters CJ et al (2015) Palivizumab epitope-displaying virus-like particles protect rodents from RSV challenge. J Clin Invest 125(4):1637–1647. https://doi.org/10.1172/JCI78450CrossRef

Roberts JN, Graham BS, Karron RA, Munoz FM, Falsey AR, Anderson LJ et al (2016) Challenges and opportunities in RSV vaccine development: meeting report from FDA/NIH workshop. Vaccine 34(41):4843–4849. https://doi.org/10.1016/j.vaccine.2016.07.057CrossRef

Langley JM, Aggarwal N, Toma A, Halperin SA, Shelly M et al (2016) A randomized, controlled, observer-blind phase I study of the safety and immunogenicity of a respiratory syncytial virus vaccine with or without alum adjuvant. J Infect Dis 215:453

Rezaee F, Linfield DT, Harford TJ, Piedimonte G (2017) Ongoing developments in RSV prophylaxis: a clinician’s analysis. Curr Opin Virol 24:70–78. https://doi.org/10.1016/j.coviro.2017.03.015CrossRef

Esposito S, Pietro GD (2016) Respiratory syncytial virus vaccines: an update on those in the immediate pipeline. Future Microbiol 11(11):1479–1490. https://doi.org/10.2217/fmb-2016-0106CrossRef

Beran J, Lickliter JD, Schwarz TF, Johnson C, Chu L, Domachowske JB et al (2018) Safety and immunogenicity of 3 formulations of an investigational respiratory syncytial virus vaccine in non-pregnant women: results from two phase II trials. J Infect Dis 217(10):1616CrossRef

10.

Crank MC, Ruckwardt TJ, Chen M, Morabito KM, Phung E, Costner PJ et al (2019) A proof of concept for structure-based vaccine design targeting RSV in humans. Science 365(6452):505–509. https://doi.org/10.1126/science.aav9033CrossRef

11.

Lambert SL, Aslam S, Stillman E, MacPhail M, Nelson C, Ro B et al (2015) A novel respiratory syncytial virus (RSV) F subunit vaccine adjuvanted with GLA-SE elicits robust protective TH1-type humoral and cellular immunity in rodent models. PLoS One 10(3):e0119509. https://doi.org/10.1371/journal.pone.0119509CrossRef

12.

Krarup A, Truan D, Furmanova-Hollenstein P, Bogaert L, Bouchier P, Bisschop IJ et al (2015) A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism. Nat Commun 6:8143. https://doi.org/10.1038/ncomms9143CrossRef

13.

Zhang Y, Qiao L, Hu X, Zhao K, Zhang Y, Chai F et al (2016) Baculovirus vectors expressing F proteins in combination with virus-induced signaling adaptor (VISA) molecules confer protection against respiratory syncytial virus infection. Vaccine 34(2):252–260. https://doi.org/10.1016/j.vaccine.2015.11.027CrossRef

14.

Chen X, Xu B, Guo J, Li C, An S, Zhou Y et al (2018) Genetic variations in the fusion protein of respiratory syncytial virus isolated from children hospitalized with community-acquired pneumonia in China. Sci Rep 8(1):4491. https://doi.org/10.1038/s41598-018-22826-4CrossRef

15.

Gilman MS, Moin SM, Mas V, Chen M, Patel NK, Kramer K et al (2015) Characterization of a prefusion-specific antibody that recognizes a quaternary, cleavage-dependent epitope on the RSV fusion glycoprotein. PLoS Pathog 11(7):e1005035. https://doi.org/10.1371/journal.ppat.1005035CrossRef

16.

Bermingham IM, Chappell KJ, Watterson D, Young PR (2017) The heptad repeat C domain of the respiratory syncytial virus fusion protein plays a key role in membrane fusion. J Virol. https://doi.org/10.1128/JVI.01323-17CrossRef

17.

McLellan JS, Chen M, Joyce MG, Sastry M, Stewart-Jones GB, Yang Y et al (2013) Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science 342(6158):592–598. https://doi.org/10.1126/science.1243283CrossRef

18.

McLellan JS, Ray WC, Peeples ME (2013) Structure and function of respiratory syncytial virus surface glycoproteins. Curr Top Microbiol Immunol 372:83–104. https://doi.org/10.1007/978-3-642-38919-1_4CrossRef

19.

Liljeroos L, Krzyzaniak MA, Helenius A, Butcher SJ (2013) Architecture of respiratory syncytial virus revealed by electron cryotomography. Proc Natl Acad Sci USA 110(27):11133–11138. https://doi.org/10.1073/pnas.1309070110CrossRef

20.

Crunkhorn S (2014) Viral diseases: zeroing in on RSV vaccine design. Nat Rev Drug Discov 13(1):17. https://doi.org/10.1038/nrd4207CrossRef

21.

Joyce MG, Zhang B, Ou L, Chen M, Chuang GY, Druz A et al (2016) Iterative structure-based improvement of a fusion-glycoprotein vaccine against RSV. Nat Struct Mol Biol 23(9):811–820. https://doi.org/10.1038/nsmb.3267CrossRef

22.

McLellan JS, Chen M, Leung S, Graepel KW, Du X, Yang Y et al (2013) Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science 340(6136):1113–1117. https://doi.org/10.1126/science.1234914CrossRef

23.

Zhang Y, Zhou Z, Zhu SL, Zu X, Wang Z, Zhang LK et al (2019) A novel RSV F-Fc fusion protein vaccine reduces lung injury induced by respiratory syncytial virus infection. Antiviral Res 165:11–22. https://doi.org/10.1016/j.antiviral.2019.02.017CrossRef

24.

Salisch NC, Izquierdo Gil A, Czapska-Casey DN, Vorthoren L, Serroyen J, Tolboom J et al (2019) Adenovectors encoding RSV-F protein induce durable and mucosal immunity in macaques after two intramuscular administrations. NPJ Vaccines 4:54. https://doi.org/10.1038/s41541-019-0150-4CrossRef

25.

Kim HW, Canchola JG, Brandt CD, Pyles G, Chanock RM, Jensen K et al (1969) Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 89(4):422–434CrossRef

26.

Delgado MF, Coviello S, Monsalvo AC, Melendi GA, Hernandez JZ, Batalle JP et al (2009) Lack of antibody affinity maturation due to poor toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nat Med 15(1):34–41. https://doi.org/10.1038/nm.1894CrossRef

27.

Ma Y, Jiao Y-Y, Yu Y-Z, Jiang N, Hua Y, Zhang X-J et al (2018) A built-in CpG adjuvant in RSV F protein DNA vaccine drives a Th1 polarized and enhanced protective immune response. Viruses 10(1):38. https://doi.org/10.3390/v10010038CrossRef

28.

Glenn GM, Smith G, Fries L, Raghunandan R, Lu H, Zhou B et al (2013) Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccine. Vaccine 31(3):524–532. https://doi.org/10.1016/j.vaccine.2012.11.009CrossRef

29.

Blais N, Gagne M, Hamuro Y, Rheault P, Boyer M, Steff AM et al (2017) Characterization of pre-F-GCN4t, a modified human respiratory syncytial virus fusion protein stabilized in a noncleaved prefusion conformation. J Virol. https://doi.org/10.1128/JVI.02437-16CrossRef

30.

Singh SR, Dennis VA, Carter CL, Pillai SR, Jefferson A, Sahi SV et al (2007) Immunogenicity and efficacy of recombinant RSV-F vaccine in a mouse model. Vaccine 25(33):6211–6223. https://doi.org/10.1016/j.vaccine.2007.05.068CrossRef

31.

Subbarayan P, Qin H, Pillai S, Lee JJ, Pfendt AP, Willing G et al (2010) Expression and characterization of a multivalent human respiratory syncytial virus protein. Mol Biol 44(3):420–430. https://doi.org/10.1134/s0026893310030106CrossRef

32.

Arcuri HA, Apponi LH, Valentini SR, Durigon EL, de Azevedo WF, Fossey MA et al (2008) Expression and purification of human respiratory syncytial virus recombinant fusion protein. Protein Expr Purif 62(2):146–152. https://doi.org/10.1016/j.pep.2008.08.005CrossRef

33.

Brunel L, Neugnot V, Landucci L, Boze H, Moulin G, Bigey F et al (2004) High-level expression of Candida parapsilosis lipase/acyltransferase in Pichia pastoris. J Biotechnol 111(1):41–50. https://doi.org/10.1016/j.jbiotec.2004.03.007CrossRef

34.

Farnos O, Fernandez E, Chiong M, Parra F, Joglar M, Mendez L et al (2009) Biochemical and structural characterization of RHDV capsid protein variants produced in Pichia pastoris: advantages for immunization strategies and vaccine implementation. Antiviral Res 81(1):25–36. https://doi.org/10.1016/j.antiviral.2008.08.007CrossRef

35.

Jing XL, Luo XG, Tian WJ, Lv LH, Jiang Y, Wang N et al (2010) High-level expression of the antimicrobial peptide plectasin in Escherichia coli. Curr Microbiol 61(3):197–202. https://doi.org/10.1007/s00284-010-9596-3CrossRef

36.

Garg R, Latimer L, Wang Y, Simko E, Gerdts V, Potter A et al (2016) Maternal immunization with respiratory syncytial virus fusion protein formulated with a novel combination adjuvant provides protection from RSV in newborn lambs. Vaccine 34(2):261–269. https://doi.org/10.1016/j.vaccine.2015.11.029CrossRef

37.

Mapletoft JW, Oumouna M, Kovacs-Nolan J, Latimer L, Mutwiri G, Babiuk LA et al (2008) Intranasal immunization of mice with a formalin-inactivated bovine respiratory syncytial virus vaccine co-formulated with CpG oligodeoxynucleotides and polyphosphazenes results in enhanced protection. J Gen Virol. 89(Pt 1):250–260. https://doi.org/10.1099/vir.0.83300-0CrossRef

38.

Lee Y, Ko EJ, Kim KH, Lee YT, Hwang HS, Jung YJ et al (2019) The efficacy of inactivated split respiratory syncytial virus as a vaccine candidate and the effects of novel combination adjuvants. Antiviral Res 168:100–108. https://doi.org/10.1016/j.antiviral.2019.05.011CrossRef

39.

Xu W, Zhao Q, Xing L, Lin Z (2016) Recombinant production of influenza hemagglutinin and HIV-1 GP120 antigenic peptides using a cleavable self-aggregating tag. Sci Rep 6:35430. https://doi.org/10.1038/srep35430CrossRef

40.

Zhao M, Zheng ZZ, Chen M, Modjarrad K, Zhang W, Zhan LT et al (2017) Discovery of a prefusion respiratory syncytial virus F-specific monoclonal antibody that provides greater in Vivo protection than the murine precursor of palivizumab. J Virol 91(15):e00176-00117. https://doi.org/10.1128/jvi.00176-17CrossRef

41.

McLellan JS (2015) Neutralizing epitopes on the respiratory syncytial virus fusion glycoprotein. Curr Opin Virol 11:70–75. https://doi.org/10.1016/j.coviro.2015.03.002CrossRef

42.

Knudson CJ, Hartwig SM, Meyerholz DK, Varga SM (2015) RSV vaccine-enhanced disease is orchestrated by the combined actions of distinct CD4 T cell subsets. PLoS Pathog 11(3):e1004757. https://doi.org/10.1371/journal.ppat.1004757CrossRef

43.

Connors M, Giese NA, Kulkarni AB, Firestone CY, Morse HC, Murphy BR (1994) Enhanced pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of interleukin-4 (IL-4) and IL-10. J Virol 68(8):5321–5325CrossRef

44.

Marasini N, Kaminskas LM (2019) Subunit-based mucosal vaccine delivery systems for pulmonary delivery - Are they feasible? Drug Dev Ind Pharm 45(6):882–894. https://doi.org/10.1080/03639045.2019.1583758CrossRef

Titel: Human respiratory syncytial virus F protein expressed in Pichia pastoris or Escherichia coli induces protective immunity without inducing enhanced respiratory disease in mice
verfasst von: Hai Li
Lei Cao
Yan Zhang
Hu Ren
Peibei Zhao
Wenbo Xu
Publikationsdatum: 06.03.2020
Verlag: Springer Vienna
Erschienen in: Archives of Virology / Ausgabe 5/2020
Print ISSN: 0304-8608
Elektronische ISSN: 1432-8798
DOI: https://doi.org/10.1007/s00705-020-04578-7

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Human respiratory syncytial virus F protein expressed in Pichia pastoris or Escherichia coli induces protective immunity without inducing enhanced respiratory disease in mice

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2020

Influence of cellular lipid content on influenza A virus replication

A novel narnavirus from the plant-pathogenic fungus Magnaporthe oryzae

Correction to: A novel narnavirus isolated from the wheat stripe rust fungus Puccinia striiformis f. sp. tritici

A novel deep-sea bacteriophage possesses features of Wbeta-like viruses and prophages

Development of a rapid and sensitive europium (III) chelate microparticle-based lateral flow test strip for the detection and epidemiological surveillance of porcine epidemic diarrhea virus

Molecular epidemiology of respiratory syncytial virus for 28 consecutive seasons (1990-2018) and genetic variability of the duplication region in the G gene of genotypes ON1 and BA in South Korea

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin